



Targeting FGFR alterations in cholangiocarcinoma and other solid tumours:

A new frontier in personalised medicine



We are delighted to invite you to Incyte's satellite symposium at ESMO 2022



10 September 2022



13:00–14:30 CEST



Room 7.2.F – Fécamp Auditorium
(Paris Expo Porte de Versailles, Paris, France)

The esteemed faculty will provide their expert perspectives on key cholangiocarcinoma topics in a series of presentations, a panel discussion and a live Q&A



Prof Filippo de Braud, Italy
Cholangiocarcinoma: The little-known, rare cancer of the biliary tract



Prof Juan Valle (Chair), UK
The challenges associated with diagnosing intrahepatic cholangiocarcinoma for targeted therapies



Dr Angela Lamarca, Spain
Optimising molecular profiling and the multidisciplinary team approach in cholangiocarcinoma



Dr David Malka (Chair), France
Clinical practice guidelines for biliary tract cancer: Updates for the management of patients with locally advanced or metastatic intrahepatic cholangiocarcinoma



Dr Antoine Hollebecque, France
Targeting FGFR alterations in cholangiocarcinoma and other solid tumours

EU/PEMA/NP/22/0014; DK/PEMA/NP/22/0009;
BE/PEMA/NP/22/0005; NL/PEMA/NP/22/0006;
CH/PEMA/NP/22/0013; ES/PEMA/NP/22/0023.

Date of preparation: July 2022

Developed and funded by Incyte Biosciences International Sàrl.

© 2022, Incyte. All rights reserved. The Incyte logo is a registered trademark of Incyte.